JZL184 treatment reduced the level of microgliosis and total Aβ in the AD mouse model. One month daily treatment with JZL184 (40 mg/kg, i.p.) reduced the immunoreactivity of (A) Iba1 in temporal (TC) (P < 0.05) and parietal (PC) (P < 0.05) cortices and hippocampus (HC) (P < 0.01) in 5-month-old tg APdE9 mice when compared to vehicle-treated mice. Also, (B) TSPO targeting radioligand [18 F]GE-180 decreased slightly but statistically non-significantly in multiple brain areas, for example, in the hippocampi. The level of (C) GFAP did not decrease significantly. The level of (D) 6E10 was reduced in TC (P < 0.001) and PC (P < 0.01) and slightly in HC.